Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame

PLoS Pathogens

Volumn 12, Issue 7, 2016, Pages

  Pons Salort, Margarita ^a   Burns, Cara C ^b   Lyons, Hil ^c   Blake, Isobel M ^a   Jafari, Hamid ^d   Oberste, M Steven ^b   Kew, Olen M ^b   Grassly, Nicholas C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSTITUTE FOR DISEASE MODELING   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE;

ARTICLE; DISEASE TRANSMISSION; GEOGRAPHIC AND GEOLOGICAL PHENOMENA; HEALTH CARE PLANNING; IMMUNIZATION; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; OUTCOME ASSESSMENT; POLIOMYELITIS; PROBABILITY; SEROTYPE; HUMAN; IMMUNOLOGY; NIGERIA; POLIOMYELITIS VIRUS; RISK FACTOR; THEORETICAL MODEL; TRANSMISSION;

HUMANS; MODELS, THEORETICAL; NIGERIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RISK FACTORS; VACCINES, ATTENUATED;

EID: 84982993448     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005728     Document Type: Article

References (39)

1. World Health Organization GPEI. The Polio Eradication & Endgame Strategic Plan 2013–2018. 2013.
2. World Health OrganizationMeeting of the Strategic Advisory Group of Experts on Immunization, November 2012—conclusions and recommendations. Wkly Epidemiol Rec. 2013;88: 1–16. 23311010
3. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA, Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59: 587–635. 16153180
4. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292: 1696–1701. 15479934
5. Centers for Disease Control and PreventionUpdate on vaccine-derived polioviruses—worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep. 2011;60: 846–850. 21716199
6. Burns CC, Diop OM, Sutter RW, Kew OM, Vaccine-derived polioviruses. J Infect Dis. 2014;210Suppl 1: S283–293. doi: 10.1093/infdis/jiu29525316847
7. World Health Organization GPEI. Reporting and classification of vaccine-derived polioviruses. 2015. Available: http://www.polioeradication.org/Portals/0/Document/Resources/VDPV_ReportingClassification.pdf.
8. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362: 2360–2369. doi: 10.1056/NEJMoa091007420573924
9. Centers for Disease Control and PreventionUpdate on vaccine-derived polioviruses—worldwide, January 2014-March 2015. MMWR Morb Mortal Wkly Rep. 2015;90: 309–320.
10. Centers for Disease Control and PreventionApparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50: 222–224. 11300627
11. Combiescu M, Guillot S, Persu A, Baicus A, Pitigoi D, Balanant J, et al. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch Virol. 2007;152: 727–738. 17195957
12. Estivariz CF, Watkins MA, Handoko D, Rusipah R, Deshpande J, Rana BJ, et al. A large vaccine-derived poliovirus outbreak on Madura Island—Indonesia, 2005. J Infect Dis. 2008;197: 347–354. doi: 10.1086/52504918199031
13. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296: 356–359. 11896235
14. Sharif S, Abbasi BH, Khurshid A, Alam MM, Shaukat S, Angez M, et al. Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June 2009-February 2011. PLoS One. 2014;9: e88442. doi: 10.1371/journal.pone.008844224558390
15. Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203: 898–909. doi: 10.1093/infdis/jiq14021402542
16. Strategic Advisory Group of Experts Polio Working Group. Conference Call Notes, Thursday, 13 March 2015. 2015. Available: http://www.who.int/immunization/sage/meetings/2015/april/2_13_March_SAGE_Polio_WG_Meeting_2_Final.pdf?ua=1.
17. Bailey NTJ, The mathematical theory of infectious diseases and its applications. 2nd edition ed. London: Griffin; 1975.
18. Gelfand HM, Leblanc DR, Fox JP, Conwell DP, Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg. 1957;65: 367–385. 13424522
19. Melnick JL, Ledinko N, Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period; the ratio of inapparent infection to clinical poliomyelitis. Am J Hyg. 1953;58: 207–222. 13080261
20. Penttinen K, Patiala R, The paralytic/infected ratio in a susceptible population during a polio type I epidemic. Ann Med Exp Biol Fenn. 1961;39: 195–202. 14038262
21. Patriarca PA, Wright PF, John TJ, Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13: 926–939. 1660184
22. Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, et al. The role of older children and adults in wild poliovirus transmission. Proc Natl Acad Sci U S A. 2014;111: 10604–10609. doi: 10.1073/pnas.132368811125002465
23. Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol. 2013;87: 4907–4922. doi: 10.1128/JVI.02954-1223408630
24. Jorba J, Campagnoli R, De L, Kew O, Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol. 2008;82: 4429–4440. doi: 10.1128/JVI.02354-0718287242
25. ICF International. Demographic and Health Surveys (various) [Nigeria 2003: NGKR4BFL.SAV, NGHR4BFL.SAV, NGGE4BFL; Nigeria 2008: NGKR52FL.SAV, NGHR52FL.SAV, NGGE52FL; Nigeria 2013: NGKR6AFL.SAV, NGHR6AFL.SAV, NGGE6AFL]. Calverton, Maryland: ICF International.
26. Burnham KP, Anderson DR, Model selection and multimodel inference: a practical information-theoretic approach. New York: Springer-Verlag; 2002.
27. Therneau TM. A Package for Survival Analysis in S. R package version 2.37–7. 2014.
28. R Core Team. R: A Language and Environment for Statistical Computing. 2015. Available: http://www.R-project.org/.
29. Mangal TD, Aylward RB, Mwanza M, Gasasira A, Abanida E, Pate MA, et al. Key issues in the persistence of poliomyelitis in Nigeria: a case-control study. Lancet Glob Health. 2014;2: e90–97. doi: 10.1016/S2214-109X(13)70168-225104665
30. Hile M, The Great North-South Divide in Nigeria. Financial Nigeria magazine. 2013November2013.
31. Kostrzewski J, Kulesza A, Abgarowicz A, The epidemic of type 3 poliomyelitis in Poland in 1968. Epidemiological Review. 1970;24: 175–189. 5431792
32. Martin J, Ferguson GL, Wood DJ, Minor PD, The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology. 2000;278: 42–49. 11112479
33. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol. 2003;77: 12460–12465. 14610170
34. Brown AE, Okayasu H, Nzioki MM, Wadood MZ, Chabot-Couture G, Quddus A, et al. Lot quality assurance sampling to monitor supplemental immunization activity quality: an essential tool for improving performance in polio endemic countries. J Infect Dis. 2014;210Suppl 1: S333–340. doi: 10.1093/infdis/jit81625316852
35. Grassly NC, Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014;210Suppl 1: S439–446. doi: 10.1093/infdis/jit60124634499
36. Hird TR, Grassly NC, Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8: e1002599. doi: 10.1371/journal.ppat.100259922532797
37. Jafari H, Deshpande JM, Sutter RW, Bahl S, Verma H, Ahmad M, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science. 2014;345: 922–925. doi: 10.1126/science.125500625146288
38. John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet. 2014.
39. Duintjer Tebbens RJ, Thompson KM, Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210Suppl 1: S485–497. doi: 10.1093/infdis/jit83825316871